SCHEMBL6029638

SCHEMBL6029638

CCOC(=O)c1nc(C)n(-c2ccccc2)n1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.75
ADORA2A P29274 1/20 0.70
ADORA1 P30542 1/20 0.70
HTT P42858 1/20 0.68
L3MBTL1 Q9Y468 1/20 0.68
PDE4D Q08499 1/20 0.58
TP53 P04637 1/20 0.55
ALOX12 P18054 1/20 0.55
ALDH1A1 P00352 6/20 0.54
KDM4E B2RXH2 4/20 0.54
HPGD P15428 2/20 0.54
HSD17B10 Q99714 1/20 0.54
GAA P10253 2/20 0.51
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
MAPT P10636 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21628361 0.86 ADORA2A (0.67) KMT2AADORA2AADORA1HTTL3MBTL1
SCHEMBL9881209 0.86 SMN1; SMN2 (0.67) KMT2AADORA2AADORA1L3MBTL1PDE4D
SCHEMBL31588064 0.86 ADORA2A (0.67) KMT2AADORA2AADORA1HTTL3MBTL1
SCHEMBL20788191 0.86 KMT2A (0.76) KMT2AADORA2AADORA1HTTL3MBTL1
SCHEMBL15760229 0.86 KMT2A (0.76) KMT2AADORA2AADORA1HTTL3MBTL1
SCHEMBL21816048 0.85 ADORA2A (0.65) KMT2AADORA2AADORA1HTTL3MBTL1
SCHEMBL4009443 0.82 ADORA2A (0.62) KMT2AADORA2AADORA1HTTL3MBTL1
SCHEMBL3111330 0.81 KMT2A (0.69) KMT2AADORA2AADORA1HTTL3MBTL1
SCHEMBL15348456 0.81 KMT2A (0.78) KMT2AADORA2AADORA1HTTL3MBTL1
SCHEMBL6029647 0.81 SMN1; SMN2 (0.68) KMT2AADORA2AADORA1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1706396-A1 N-(4-CARBAMIMIDOYL-BENZYL)-2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA F.HOFFMANN-LA ROCHE AG (CH) 2006-10-04 EP disclosed
US-7056932-B2 Heterocyclyl substituted 1-alkoxy acetic acid amides HOFFMAN-LA ROCHE INC. (US) 2006-06-06 US disclosed
WO-2005058868-A1 N-(4-CARBAMIMIDOYL-BENZYL) -2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137168-A1 Heterocyclyl substituted 1-alkoxy acetic acid amides HOFFMANN-LA ROCHE INC. 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137168-A1 Heterocyclyl substituted 1-alkoxy acetic acid amides F12, TFPI, F11 KMT2A 2080/4885ADORA2A 392/4885ADORA1 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.